Evaluation of Renal Impairment Influence on Metabolic Drug Clearance using a Modelling Approach

Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2020;395:709–33.

Article  Google Scholar 

Meier P, Saudan P, Burnier M, Martin PY. Comorbidité et facteurs de risque cardiovasculaire liés à l’insuffisance rénale chronique. Médecine Hygiène. 2003;61:441–50.

Google Scholar 

Santos-Díaz G, Pérez-Pico AM, Suárez-Santisteban MÁ, García-Bernalt V, Mayordomo R, Dorado P. Prevalence of potential drug-drug interaction risk among chronic kidney disease patients in a Spanish hospital. Pharmaceutics. 2020;12:713.

Article  Google Scholar 

Marquito AB, da Fernandes NMS, Colugnati FAB, de Paula RB, Marquito AB, da Fernandes NMS, et al. Interacoes medicamentosas potenciais em pacientes com doenca renal cronica. Braz J Nephrol. 2014;36:26–34.

Article  Google Scholar 

Rama M, Viswanathan G, Acharya LD, Attur RP, Reddy PN, Raghavan SV. Assessment of drug-drug interactions among renal failure patients of nephrology ward in a south Indian tertiary care hospital. Indian J Pharm Sci. 2012;74:63.

Article  Google Scholar 

Reidenberg MM. The biotransformation of drugs in renal failure. Am J Med. 1977;62:482–5.

Article  CAS  Google Scholar 

Mallikaarjun S, Shoaf SE, Boulton DW, Bramer SL. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. Clin Pharmacokinet. 2008;47:533–42.

Article  CAS  Google Scholar 

Bauman JW, Antal JM, Adams LM, Johnson BM, Murray SC, Peng B, et al. Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist. Invest New Drugs. 2012;30:662–71.

Article  CAS  Google Scholar 

Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol. 2002;53:21S-30S.

Article  CAS  Google Scholar 

Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012;23:1258–70.

Article  CAS  Google Scholar 

Yeung CK, Shen DD, Thummel KE, Himmelfarb J. Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int. 2014;85:522–8.

Article  CAS  Google Scholar 

Barnes KJ, Rowland A, Polasek TM, Miners JO. Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins. Eur J Clin Pharmacol. 2014;70:1097–106.

Article  CAS  Google Scholar 

Velenosi TJ, Feere DA, Sohi G, Hardy DB, Urquhart BL. Decreased nuclear receptor activity and epigenetic modulation associates with down-regulation of hepatic drug-metabolizing enzymes in chronic kidney disease. FASEB J. 2014;28:5388–97.

Article  CAS  Google Scholar 

Tsujimoto M, Sugimoto S, Nagatomo M, Furukubo T, Izumi S, Yamakawa T, et al. Possibility of decrease in CYP1A2 function in patients with end-stage renal disease. Ther Apher Dial. 2014;18:174–80.

Article  CAS  Google Scholar 

Matsuo K, Yamamoto S, Wakamatsu T, Takahashi Y, Kawamura K, Kaneko Y, et al. Increased proinflammatory cytokine production and decreased cholesterol efflux due to downregulation of ABCG1 in macrophages exposed to indoxyl sulfate. Toxins. 2015;7:3155–66.

Article  CAS  Google Scholar 

Gu X, Ke S, Liu D, Sheng T, Thomas PE, Rabson AB, et al. Role of NF-κB in Regulation of PXR-mediated gene expression A mechanism for the suppression of cytochrome P-450 3A4 BY proinflammatory agents. J Biol Chem. 2006;281:17882–9.

Article  CAS  Google Scholar 

Watanabe H, Sugimoto R, Ikegami K, Enoki Y, Imafuku T, Fujimura R, et al. Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism. Biochem Pharmacol. 2017;145:192–201.

Article  CAS  Google Scholar 

Dreisbach AW, Lertora JJL. The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial. 2003;16:45–50.

Article  Google Scholar 

Rowland-Yeo K, Aarabi M, Jamei M, Rostami-Hodjegan A. Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol. 2011;4:261–74.

Article  Google Scholar 

Yoon S, Yi S, Rhee S, Lee HA, Kim Y, Yu K-S, et al. Development of a physiologically-based pharmacokinetic model for cyclosporine in Asian children with renal impairment. Transl Clin Pharmacol. 2019;27:107–14.

Article  Google Scholar 

Lu C, Suri A, Shyu WC, Prakash S. Assessment of cytochrome P450-mediated drug–drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. Biopharm Drug Dispos. 2014;35:543–52.

Article  CAS  Google Scholar 

Bergman A, Bi Y, Mathialagan S, Litchfield J, Kazierad DJ, Pfefferkorn JA, et al. Effect of hepatic organic anion-transporting polypeptide 1B INHIBITION AND CHRONIC KIDNEY DISEASE ON THE PHARMACOKINETICS OF A LIVER-TARGETED GLUCOKINASE ACTIVATOR: A MODEL-BASED EVALUATIOn. Clin Pharmacol Ther. 2019;106:792–802.

Article  CAS  Google Scholar 

Steelandt J, Jean-Bart E, Goutelle S, Tod M. A prediction model of drug exposure in cirrhotic patients according to Child-Pugh classification. Clin Pharmacokinet. 2015;54:1245–58.

Article  Google Scholar 

Ohno Y, Hisaka A, Ueno M, Suzuki H. General framework for the prediction of oral drug interactions caused by CYP3A4 Induction from in vivo information. Clin Pharmacokinet. 2008;47:669–80.

Article  CAS  Google Scholar 

Tod M, Goutelle S, Clavel-Grabit F, Nicolas G, Charpiat B. Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions. Clin Pharmacokinet. 2011;50:519–30.

Article  CAS  Google Scholar 

Gabriel L, Tod M, Goutelle S. Quantitative prediction of drug interactions caused by CYP1A2 inhibitors and inducers. Clin Pharmacokinet. 2016;55:977–90.

Article  CAS  Google Scholar 

Goutelle S, Bourguignon L, Bleyzac N, Berry J, Clavel-Grabit F, Tod M, et al. In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates. AAPS J. 2013;15:415–26.

Article  CAS  Google Scholar 

Levey AS, Eckardt K-U, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–100.

Article  Google Scholar 

Rowland M, Matin SB. Kinetics of drug-drug interactions. J Pharmacokinet Biopharm. 1973;1:553–67.

Article  CAS  Google Scholar 

Nakazawa R, Kaneko M, Hoshi H, Kim T, Nakamura M, Azuma N, et al. Liver blood flow in chronic hemodialysis patients. Nephron. 1996;73:396–402.

Article  Google Scholar 

Quantitative prediction of drug drug interactions-DDI-Predictor Academic version [Internet]. 2020. https://www.ddi-predictor.org/. Accessed 16 Dec 2020.

Hsu C-Y, Bates DW, Kuperman GJ, Curhan GC. Relationship between hematocrit and renal function in men and women. Kidney Int. 2001;59:725–31.

Article  CAS  Google Scholar 

Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899–911.

Article  CAS  Google Scholar 

Aparicio M, Chauveau P, Précigout VD, Bouchet J-L, Lasseur C, Combe C. Nutrition and outcome on renal replacement therapy of patients with chronic renal failure treated by a supplemented very low protein diet. J Am Soc Nephrol. 2000;11:708–16.

Article  Google Scholar 

Rein - Analyse d’ordonnance [Internet]. SiteGPR. http://sitegpr.com/fr/rein/analyse-dordonnance/. Accessed 12 Feb 2021.

DrugBank | Pharmaceutical Knowledge Base | API Integrations [Internet]. https://www.drugbank.com/. Accessed 7 Jan 2021.

Abbas R, Hsyu P-H. Clinical pharmacokinetics and pharmacodynamics of bosutinib. Clin Pharmacokinet. 2016;55:1191–204.

Article  CAS  Google Scholar 

Barbhaiya RH, Shukla UA, Pfeffer M, Pittman KA, Shrotriya R, Laroudie C, et al. Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. Eur J Clin Pharmacol. 1994;46:41–7.

Article  CAS  Google Scholar 

Caccia S, Vigano GL, Mingardi G, Garattini S, Gammans RE, Placchi M, et al. Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. Clin Pharmacokinet. 1988;14:171–7.

Article  CAS  Google Scholar 

Wason S, Mount D, Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin Drug Investig. 2014;34:845–55.

Article  CAS  Google Scholar 

Tan W, Yamazaki S, Johnson TR, Wang R, O’Gorman MT, Kirkovsky L, et al. Effects of renal function on crizotinib pharmacokinetics: dose recommendations for patients with ALK-positive non-small cell lung cancer. Clin Drug Investig. 2017;37:363–73.

Article  CAS  Google Scholar 

Nichols AI, Richards LS, Behrle JA, Posener JA, McGrory SB, Paul J. The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment. Int J Clin Pharmacol Ther. 2011;49:3–13.

Article  CAS  Google Scholar 

Ravis WR, Reid S, Sica DA, Tolbert DS. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J Clin Pharmacol. 2005;45:810–21.

Article  CAS  Google Scholar 

Dunselman P, Edgar B, Scaf A, Kuntze C, Wesseling H. Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure. Br J Clin Pharmacol. 1989;28:45–52.

Article  CAS  Google Scholar 

Larsson R, Karlberg BE, Gelin A, Åberg J, Regårdh C-G. Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. J Clin Pharmacol. 1990;30:1020–30.

Article  CAS  Google Scholar 

Appel-Dingemanse S, Smith T, Merz M. Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome. J Clin Pharmacol. 2002;42:312–8.

留言 (0)

沒有登入
gif